All In Biotech

Drug Trial Radar · NCT01852292

Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy

Double Blind, Placebo Controlled Study Assessing the Efficacy of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Patients With Platinum Pre-treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Last checked: Nov 20, 2026Latest source record: Jul 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 157 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

157

Actual

Start

Oct 1, 2013

Primary completion

Mar 30, 2017

Study completion Mar 30, 2017

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 13, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase II Study of efficacy and safety of buparlisib (BKM120) plus paclitaxel versus placebo plus paclitaxel in recurrent or metastatic Head and Neck cancer previously pre-treated with a platinum therapy.The primary endpoint was PFS and the key secondary endpoint was Overall Survival.

Conditions

  • Head and Neck Squamous Cell Carcinoma

Interventions

  • BuparlisibDrug

    Buparlisib comes in gelatin capsules and is taken orally at a dose of 100 mg/day.

  • Buparlisib matching PlaceboDrug

    Buparlisib matching placebo comes in gelatin capsules and is taken orally at a dose of 100 mg/day.

  • PaclitaxelDrug

    Paclitaxel is an intravenous infusion that is given once every week in 80 mg/m\^2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) Per Investigator AssessmentTime frame: 4 weeks and thereafter every 6 weeks until disease progression or death up to 3.5 years

Locations

58 sites in 18 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group

    Fayetteville, Arkansas

  • Dana Farber Cancer Institute IRB

    Boston, Massachusetts

  • Washington U School of Medicine Center for Clinical Studies SC - BKM120H2201

    St Louis, Missouri

  • The Mount Sinai Hospital Dept of Oncology

    New York, New York

  • University of N.C. at Chapel Hill Lineberger Comp. Cancer Ctr.

    Chapel Hill, North Carolina

  • University Hospitals Case Medical Center Univ. Hospitals of Cleveland

    Cleveland, Ohio

  • UPMC Cancer Centers BKM120H2201

    Pittsburgh, Pennsylvania

  • Novartis Investigative Site

    St Leonards, New South Wales, Australia

  • Novartis Investigative Site

    Hamilton, Ontario, Canada

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Saint-Herblain, France

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Hanover, Germany

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Nyíregyháza, Hungary

  • Novartis Investigative Site

    Kerala, India

  • Novartis Investigative Site

    Mumbai, India

  • Novartis Investigative Site

    Nashik, Maharashtra, India

  • Novartis Investigative Site

    Dehli, New Delhi, India

  • Novartis Investigative Site

    Jaipur, Rajasthan, India

  • Novartis Investigative Site

    Kolkata, West Bengal, India

  • Novartis Investigative Site

    Dublin, Ireland

  • Novartis Investigative Site

    Florence, FI, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Palermo, PA, Italy

  • Novartis Investigative Site

    Roma, RM, Italy

  • Novartis Investigative Site

    Salerno, SA, Italy

  • Novartis Investigative Site

    Torino, TO, Italy

  • Novartis Investigative Site

    Venezia, VE, Italy

  • Novartis Investigative Site

    Kashiwa, Chiba, Japan

  • Novartis Investigative Site

    Koto-ku, Tokyo, Japan

  • Novartis Investigative Site

    Minato-ku, Tokyo, Japan

  • Novartis Investigative Site

    Warsaw, Poland

  • Novartis Investigative Site

    Nizhny Novgorod, Russia

  • Novartis Investigative Site

    Saint Petersburg, Russia

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.